Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. (2020)
Attributed to:
Tropical Infectious Disease Consortium: Expanding and Accelerating Product
Development
funded by
UKRI
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/cpt.1909
PubMed Identifier: 32438446
Publication URI: http://europepmc.org/abstract/MED/32438446
Type: Journal Article/Review
Volume: 108
Parent Publication: Clinical pharmacology and therapeutics
Issue: 4
ISSN: 0009-9236